3McGettigan P,Henry D.Cardiovascular Risk and Inhibition of Cyclooxygenase:A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase[J]. JAMA,2006,296(13):1633-1644.
4Weng-Foung Huang,Fei-Yuan Hsiao,Yu-Wen Wen,et al.Cardiovascular Events Associated with the Use of Four Nonselective NSAIDs (Etodolac,Nabumetone,Ibuprofen,or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib):A Population-Based Analysis in Taiwan Residents Adults[J]. Clinical Therapeutics,2006,28(11):1827-1836.
5David J Graham,David Campen,Rita Hui,et al.Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs:nested case-control study[J]. Lancet,2005,365:475-481.
6Christianne LR,Neesha NC,Kaltenbach MS,et al.Non-aspirin NSAIDs,cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke,acute myocardial infarction,and death from coronary heart disease[J]. Pharmacoepidemiology and drug safety,2009,18:1053-1063.
7Marianne C,David W,Nawab Q,et al.Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis[J]. Pharmacoepidemiology and drug safety,2008,17:601-608.
8Loren L,William BW,Alaa R,et al.COX-2 Selective Inhibitors in the Treatment of Osteoarthritis[J]. Semin Arthritis Rheum,2008,38:165-187.
1Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000, 43: 1905-1915.
2Schnitzer TJ, American College of Rheumatology. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage, 2002, 23(4 Suppl): S24-34.
3Hochberg MC, Ahman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part Ⅱ. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum, 1995, 38:1541-1546.
4Hochberg MC, Ahman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part Ⅰ. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum, 1995, 38: 1535-1540.
5Simon LS, Lipman AG, Jacox AK, eds. Pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. 2nd ed. Glenview (IL): American Pain Society (APS), 2002. 179.
6Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2007, 66: 377-388.
7Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology. Br J Sports Med, 2006, 40: 664-669.
8Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2000, 59: 936-944.
9Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2005, 64: 669-681.
10Chevalier X, Marre JP, de Butler J, et al. Questionnaire survey of management and prescription of general practitioners in knee osteoarthritis: a comparison with 2000 EULAR recommendations. Clin Exp Rheumatol, 2004, 22: 205-212.
